Approval · Notice of Compliance 25960 · 2021
ADVATE: Notice of Compliance 25960
Issued May 27, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25960
- Date
- May 27, 2021
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Transfer of drug identification number
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADVATE | 02365952 | Dormant |
| ADVATE | 02284154 | Dormant |
| ADVATE | 02365979 | Approved |
| ADVATE | 02284162 | Dormant |
| ADVATE | 02365987 | Approved |
| ADVATE | 02313111 | Dormant |
| ADVATE | 02337193 | Dormant |
| ADVATE | 02246405 | — |
| ADVATE | 02446413 | Approved |
| ADVATE | 02446421 | Approved |
| ADVATE | 02446448 | Approved |
| ADVATE | 02365944 | Dormant |
| ADVATE | 02446456 | Approved |
| ADVATE | 02446464 | Approved |
Medicinal ingredients
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) 250 MG per ML
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) 500 MG per ML
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) 1,000 MG per ML
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) 1,500 MG per ML
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) 2,000 MG per ML
- ANTIHEMOPHILIC FACTOR (RECOMBINANT) 3,000 MG per ML